---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-035376"
form_type: "8-K"
ticker: "REVB"
cik: "0001810560"
company_name: "REVELATION BIOSCIENCES, INC."
filed_at: "2024-03-22T23:59:59+00:00"
generated_at: "2026-06-04T09:10:46.064065+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Revelation Biosciences FY2023 net loss narrows to $0.1M; cash $12.0M through 2024

## Summary
- Year-end cash $12.0M vs $5.3M; company believes sufficient to fund operations through 2024.
- Net loss for FY2023 $0.1M (EPS -$0.53) vs $10.8M loss ($149.20 EPS) in 2022, due to $8.3M warrant liability gain.
- Q4 2023 net loss $2.2M ($8.33 EPS) vs $1.2M loss ($15.61 EPS) in Q4 2022; operating cash burn $2.0M.
- Completed $6.2M public offering; began Phase 1 study of Gemini; presented positive preclinical AKI data.
- Net cash used in operations for FY2023 was $7.3M, down from $11.2M in 2022.

## SEC filing metadata
- accession: 0000950170-24-035376
- form_type: 8-K
- ticker: REVB
- cik: 0001810560
- company_name: REVELATION BIOSCIENCES, INC.
- filed_at: 2024-03-22T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810560/000095017024035376/0000950170-24-035376-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810560/000095017024035376/revb-20240322.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-035376
- JSON: https://secwatch.observer/filing/0000950170-24-035376.json
- Plain text: https://secwatch.observer/filing/0000950170-24-035376.txt

## Key facts
- Earnings Releases
  REVELATION BIOSCIENCES, INC. reported twelve months ended December 31, 2023 results: net income net loss of $0.1 million, EPS $0.53 basic and diluted net loss per share.
  - Period: twelve months ended December 31, 2023
  - Net income: net loss of $0.1 million
  - EPS: $0.53 basic and diluted net loss per share
  - Result: reported results
  source text: Revelation’s net loss for the three and twelve months ended December 31, 2023 was $2.2 million and $0.1 million, or $8.33 and $0.53 basic and diluted net loss per share, respectively
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810560/000095017024035376/0000950170-24-035376-index.htm
- Earnings Releases
  REVELATION BIOSCIENCES, INC. reported three months ended December 31, 2023 results: net income net loss of $2.2 million, EPS $8.33 basic and diluted net loss per share.
  - Period: three months ended December 31, 2023
  - Net income: net loss of $2.2 million
  - EPS: $8.33 basic and diluted net loss per share
  - Result: reported results
  source text: Revelation’s net loss for the three and twelve months ended December 31, 2023 was $2.2 million and $0.1 million, or $8.33 and $0.53 basic and diluted net loss per share, respectively
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810560/000095017024035376/0000950170-24-035376-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.